Boardroom Alpha
Start trial
10-K primary document
UTHR · Annual Report (Form 10-K) · Filed February 25, 2026

United Therapeutics Corp — 10-K exhibit

uthrexh10451231202510k.htm
United Therapeutics Corp on Boardroom Alpha
Document
Exhibit 10.45
Thirteenth Amendment
To
Wholesale Product Purchase Agreement

THIS THIRTEENTH AMENDMENT TO WHOLESALE PRODUCT PURCHASE AGREEMENT (this “Thirteenth Amendment”) is made as of the date the last Party executes this Thirteenth Amendment (the “Amendment Effective Date”), by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having offices at 255 Technology Park, Lake Mary, Florida 32746, (“Distributor”), and United Therapeutics Corporation (“UT”), a Delaware public benefit corporation having offices at 55 TW Alexander Dr., Durham, NC 27709. Distributor and UT are each referred to in this Agreement as a “Party,” collectively, the “Parties.”

WHEREAS, the Parties entered into that certain Wholesale Product Purchase Agreement (as amended, the “Agreement”), dated as of January 1, 2018; and

WHEREAS, the Parties desire to amend the Agreement as provided herein, with effect from the Amendment Effective Date.

NOW THEREFORE, in consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound, hereby agree as follows:

1.Exhibit A to the Agreement is hereby deleted in its entirety and is replaced with the Exhibit A attached to this Thirteenth Amendment.

2.Except as amended and supplemented hereby, all of the terms and conditions of the Agreement shall remain and continue in full force and effect and apply hereto.

IN WITNESS WHEREOF, each of the undersigned, duly authorized, has executed this Thirteenth Amendment, effective as of the Amendment Effective Date.


PRIORITY HEALTHCARE DISTRIBUTION, INC.

By:    /s/ Earl English
            
Print Name: Earl English

Title:    President, Curascript SD

Date: 4/10/2025
UNITED THERAPEUTICS CORPORATION

 By:    /s/ Chip Jackson    
            
Print Name: Chip Jackson

Title:    VP Distribution and Patient Access

Date: 17-Apr-2025 | 5:56:04 PM EDT

1

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer